Vestal Point Capital’s Xenon Pharmaceuticals XENE Stock Holding History

Vestal Point Capital’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$42.3M	Buy	700,000 +60,100	+9%	+$3.34M	0.99%	30
2026 Q1	$37.2M	Buy	639,900 +39,900	+7%	+$1.84M	1.04%	34
2025 Q4	$26.9M	Sell	600,000 -500,000	-45%	-$21M	0.91%	33
2025 Q3	$44.2M	Sell	1,100,000 -900,000	-45%	-$31.7M	1.99%	17
2025 Q2	$62.6M	Buy	2,000,000 +700,000	+54%	+$22.8M	3.3%	7
2025 Q1	$43.6M	Buy	1,300,000 +490,000	+60%	+$18.6M	3.11%	9
2024 Q4	$31.8M	Sell	810,000 -15,000	-2%	-$620K	1.88%	21
2024 Q3	$32.5M	Buy	825,000 +300,000	+57%	+$12.1M	2.46%	16
2024 Q2	$20.5M	Buy	525,000 +125,000	+31%	+$5M	1.53%	24
2024 Q1	$17.2M	Buy	400,000 +225,000	+129%	+$10.3M	1.42%	17
2023 Q4	$8.06M	Buy	+175,000	New	+$6.18M	0.85%	29

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Vestal Point Capital's XENE Position: Q2 2026 in Review

Vestal Point Capital increased its Xenon Pharmaceuticals (XENE) stake by 9.4% in Q2 2026, buying an estimated $3.34M and bringing the position to 700,000 shares worth $42.3M. The position accounts for 0.99% of the portfolio, ranked #30.

Vestal Point Capital first reported a position in XENE in Q4 2023 and has held it in 11 quarters since. The position peaked at $62.6M in Q2 2025. 316 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

Vestal Point Capital held 700,000 shares of Xenon Pharmaceuticals worth $42.3M as of Q2 2026.
Vestal Point Capital bought 60,100 Xenon Pharmaceuticals shares in Q2 2026, an estimated $3.34M.
Xenon Pharmaceuticals made up 0.99% of Vestal Point Capital's portfolio in Q2 2026, its #30 holding.
Vestal Point Capital first reported a position in Xenon Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
Vestal Point Capital's Xenon Pharmaceuticals position peaked at $62.6M in Q2 2025.
316 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Vestal Point Capital's 13F filing for Q2 2026, filed 14 Aug 2026.